YOLFTbeta
Kangstem Biotech Co. Ltd

Kangstem Biotech Co. Ltd

217730 · KQ · Healthcare / Biotechnology

1,763.00KRW-24.00 (-1.34%)

Price History

Full chart

Market Stats

Previous Close1,787.00
Open1,800.00
Day Range1,744.00 – 1,830.00
52-Week Range1,372.00 – 4,690.00
Volume127.31K
Market Cap213.97B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.42
50-Day Avg2,273.88
200-Day Avg2,567.01

About

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOJong-Cheon Na
  • Employees100
  • HeadquartersSinan Building, Seoul, South Korea, 06179, Korea
  • Websitehttps://www.kangstem.com

Leadership

  • Jong-Cheon NaChief Executive Officer
  • Prof. Kyung-Sun KangFounder · b. 1963
  • Mr. Tae-Wha LeeSenior Vice President and Internal Director · b. 1961
  • Dr. Kwang-Won SeoVice President and Internal Director · b. 1966

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.48B842.80M9.13B9.17B6.00B9.14B12.40B16.30B5.91B7.75B3.57B
Growth (%)--43.23%+983.64%+0.36%-34.49%+52.18%+35.75%+31.41%-63.73%+31.00%-53.88%
Cost of Revenue252.81M57.69M5.87B7.99B6.43B8.09B9.72B11.43B3.43B3.42B2.73B
Gross Profit1.23B785.12M3.26B1.18B-424.36M1.05B2.69B4.87B2.48B4.33B845.01M
Gross Margin82.97%93.16%35.68%12.84%-7.07%11.44%21.68%29.89%42.00%55.84%23.65%
Operating Expense6.36B9.90B16.20B13.38B23.66B20.97B25.41B25.26B22.14B19.07B18.51B
Operating Income-5.13B-9.12B-12.94B-12.21B-24.08B-19.93B-22.72B-20.38B-19.66B-14.74B-17.67B
Operating Margin-345.23%-1081.81%-141.66%-133.17%-401.08%-218.07%-183.18%-125.06%-332.48%-190.35%-494.56%
EBITDA--------15.58B-18.33B-3.43B-7.61B
EBITDA Margin--------95.60%-309.99%-44.29%-213.03%
Net Income-5.75B-8.30B-15.42B-13.65B-24.63B-18.47B-21.35B-20.24B-21.95B-7.67B-10.48B
Net Income Margin-387.59%-984.85%-168.87%-148.91%-410.26%-202.14%-172.10%-124.14%-371.22%-99.01%-293.41%
R&D-5.53B6.71B6.18B12.42B12.64B14.65B14.22B14.03B12.14B12.58B
R&D as % of Total Revenue-656.04%73.52%67.44%206.77%138.31%118.12%87.24%237.29%156.77%352.06%
Interest Expense00000560.71M761.09M761.13M893.42M425.94M492.67M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%6.14%6.14%4.67%15.11%5.50%13.79%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets24.98B47.44B45.91B73.19B113.64B82.51B103.15B80.59B81.25B55.99B81.49B
Total Liabilities3.75B24.46B22.44B25.50B42.92B30.89B35.07B33.33B36.74B12.80B12.43B
Total Equity21.24B22.98B23.47B47.69B70.72B51.62B68.07B49.37B48.01B43.18B68.65B
Cash4.99B908.52M2.79B2.88B7.47B9.97B7.54B4.68B5.86B2.77B1.97B
Total Debt780.00M15.55B16.98B5.84B18.34B14.87B-----
Net Debt----14.54B-3.85B6.82B5.67B3.94B5.77B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.80B-7.80B-10.65B-11.48B-13.32B-13.99B-16.99B-18.86B-16.50B-18.99B-11.68B
Investing Cash Flow-12.06B-26.72B6.47B-25.83B-38.13B29.85B-24.78B16.24B-2.30B15.01B-
Financing Cash Flow21.49B30.17B6.16B36.62B55.91B-13.57B39.29B-231.40M19.98B884.21M-
Capital Expenditure1.04B1.68B8.12B1.61B15.34B3.04B4.63B712.42M1.41B593.45M660.84M
Free Cash Flow------17.05B-21.64B-19.71B-17.91B-19.58B-12.34B
FCF to OCF-----121.82%127.37%104.49%108.54%103.13%105.66%

Earnings

Report DateFeb 12, 2016May 16, 2016Aug 16, 2016Nov 14, 2016Feb 9, 2017May 15, 2017Aug 29, 2017Nov 14, 2017Feb 6, 2018May 10, 2018Aug 14, 2018Jan 25, 2019May 15, 2019Aug 14, 2019Nov 13, 2019Jan 31, 2020May 14, 2020Aug 13, 2020Nov 16, 2020Jan 29, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------
EPS Actual-133.79-113.36-153.74-135.47-256.45-175.49-187.08-259.4630.1448.94-307.50-743.95-186.13-268.70-214.26-430.55-315.08-119.48-130.99-171.49-137.70-108.20-139.90-164.09-103.10-95.53-109.51-98.39-111.83-118.10-121.58-78.26-59.3270.23-60.14-65.33-73.16-71.88-62.5039.30-48.49-66.44
Surprise------------------------------------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hours----------------------

Key Statistics & Ratios

Market Cap213.97B
Enterprise Value175.53B
Trailing P/E0.00
Forward P/E0.00
Price / Sales70.51
Price / Book3.43
Revenue (TTM)3.03B
Gross Profit (TTM)413.99M
EBITDA-17.13B
Profit Margin0.00%
Operating Margin-944.26%
Return on Equity-47.88%
Return on Assets-17.58%
Shares Outstanding94.05M
Shares Float71.21M
Beta0.42
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 10, 20251687:1411
  • Sep 15, 2023969:883
  • Sep 2, 20211273:1115
  • Jun 15, 20181243:1172